{
  "name": "Rapamycin Alternatives (Rapalogs)",
  "category": "pharmaceutical",
  "evidenceGrade": "C",
  "riskProfile": "medium",
  "description": "Next-generation mTOR inhibitors and rapalogs designed for better tolerability than rapamycin. Includes everolimus (RTB101) and newer compounds specifically targeting mTORC1 over mTORC2 to reduce side effects while maintaining longevity benefits.",
  "mechanisms": [
    "Selective mTORC1 inhibition",
    "Autophagy induction",
    "Immune function enhancement (low doses)",
    "Senescent cell regulation"
  ],
  "dosage": {
    "standard": "Variable by compound â€” physician-guided",
    "range": "Everolimus 0.5mg/week typical",
    "notes": "Prescription only. Replicel (RTB101/everolimus) showed immune enhancement in elderly at low dose. Goal: mTORC1 inhibition without mTORC2 suppression."
  },
  "keyFindings": [
    "Low-dose everolimus enhanced immune response to flu vaccine in elderly by 20% (Mannick et al., Science Translational Medicine)",
    "More selective mTORC1 targeting may avoid rapamycin side effects",
    "RTB101 (everolimus derivative) in clinical trials for immune aging"
  ],
  "interactions": [
    "CYP3A4 substrates",
    "Strong CYP3A4 inhibitors/inducers",
    "Vaccines (may affect response)"
  ],
  "sideEffects": [
    "Mouth sores",
    "Delayed wound healing",
    "Metabolic changes",
    "Infections (high doses)"
  ],
  "contraindications": [
    "Active infections",
    "Severe hepatic impairment",
    "Immunosuppressed patients"
  ],
  "tags": [
    "pharmaceutical",
    "mtor",
    "rapalog",
    "immune",
    "autophagy",
    "prescription"
  ],
  "estimatedMonthlyCost": {
    "low": 30,
    "mid": 80,
    "high": 200,
    "currency": "USD"
  },
  "id": "prod-rapamycin-alternatives-rapalogs",
  "sources": [],
  "suppliers": [],
  "communityReports": [],
  "expertOpinions": [],
  "lastUpdated": "2026-02-04T14:50:14.858Z",
  "createdAt": "2026-02-04T14:50:14.858Z"
}